RE: Undervalued Massively5 Feb 2021 14:39
It may be worth staying mindful that both GSK and ULVR
were hammered on results, there may be increased volatility next
week and quite possibly some downside. With AZN, expectations
are high.
The bullish case here is multi year, providing AZN continue to
deliver inline.
Currently the London market strongly favours cyclical and covid recovery
stocks. Defensives are not in favour, at least that's very much how it
looks to me.
If anyone feels nervous or uneasy, then look at your position size.
Anyone running a margined position on AZN in to results may
either be brave or foolish, or possibly both!.